Novavax, Inc. (NVAX)
After hours:
| Previous Close | 5.76 |
| Open | 5.73 |
| Bid | 6.01 x 900 |
| Ask | 6.02 x 1400 |
| Day's Range | 5.71 - 6.13 |
| 52 Week Range | 5.61 - 82.30 |
| Volume | |
| Avg. Volume | 6,775,821 |
| Market Cap | 513.424M |
| Beta (5Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373). This agreement will maintain the U.S. public's access to Novavax' vaccine and suppo
- CNW Group
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock. In connection with the common stock offering, Novavax granted the underwriters a 30-day option to purchase up to an additional 975,000 s
- CNW Group
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the "notes"). The notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with
